BeOne Medicines Ltd. Class A

BeOne Medicines Ltd.'s next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, BeOne Medicines Ltd. has 2.05B shares outstanding.

As of June 30, 2026, BeOne Medicines Ltd. maintains a current ratio of 3.40, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 22.10, indicating elevated leverage, while an interest coverage ratio of 14.84 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, BeOne Medicines Ltd. posted a return on equity (ROE) of 14.66, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 12.18 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 8.47, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 12.79, useful for judging operating efficiency across full business cycles. The company generates approximately 456,568.62 in revenue per employee across its workforce of 11,750.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.10 indicates how many times BeOne Medicines Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, BeOne Medicines Ltd. recorded 185.89M in income tax expense. That works out to an effective tax rate of 24.46, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 759.83M, leaving 573.94M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended June 30, 2026, BeOne Medicines Ltd. generated 5.36B in revenue and converted that into 573.94M in net income, yielding earnings per share of 0.30. EBITDA reached 943.60M, while operating income came in at 807.99M.

As of June 30, 2026, BeOne Medicines Ltd. holds 4.46B in cash and equivalents against 1.00B in total debt, resulting in a net debt position of -3.52B. Total book value stands at 4.53B, with working capital of 4.46B providing operational flexibility.

BeOne Medicines Ltd. produced 1.30B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -153.25M in capital expenditures, free cash flow totaled 1.15B - equivalent to 0.61 per share.

Over the twelve months ended June 30, 2026, BeOne Medicines Ltd. posted a gross margin of 88.89, reflecting its pricing power and cost economics. The operating margin of 15.06 and net profit margin of 10.70 provide insight into operational efficiency.